Recombinant Human IFN-ω #abs00919

abs00919-20ug

1-2 Weeks

138

abs00919-100ug

1-2 Weeks

344

abs00919-1mg

1-2 Weeks

1425

Species

Human

Source

Escherichia coli.

Format

The concentrated solution in PBS, pH 7.4 was filtered through a 0.2 μm filter and then lyophilized to produce the current state. We can generate content with a similar meaning by rephrasing this information as follows: After concentrating the solution in PBS to pH 7.4, it was filtered using a 0.2 μm filter. The resultant filtered solution was then lyophilized to yield the current form.

Properties

aa_sequence

SGLHAETQLR LSLQRSVLMH RMHFPLISRR RRFQRFDDPK QSQGLKVELM LHHELMISAV NSLFQIFHTL ASQTAHWAML TGLQHGTHLQ CLTCHQHLQV GSEAGAESLV LATPSGSASI RYIVQFRGQK CSDEDKAKSQ VREMIMEWCV SLTNQMFSLS GGDLSKNRDR.

Concentration

> 97 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The LAL method determined that the Recombinant HumanIFN-ω has a content of less than 1 EU/μg. This information is based on the original text.

Activity

When compared to the standard, the ED is fully biologically active. I would like to generate a highly similar content by rearranging the given text. Please note that I will provide the content based on the original information but using a completely different approach in language modeling.₅₀The chemotaxis bioassay conducted on human TF-1 cells has revealed that the concentration of the protein in question is less than 0.01 ng/ml. Moreover, the protein has a particularly impressive specific activity or potency, measuring greater than 1.0 × 10. These findings are significant as they indicate that even at extremely low doses, this protein can still have a potent biological effect.⁸ IU/mg.

Reconstitution

Before opening, it is recommended to briefly centrifuge the vial to settle the contents at the bottom. To prepare, reconstitute in either sterile distilled water or an aqueous buffer containing 0.1% BSA to achieve a concentration of 0.1-1.0 mg/mL. Prior to storage at ≤ -20 °C, divide the stock solutions into working aliquots. For further dilutions, use appropriate buffered solutions.

Stability & Storage

For optimal storage conditions, the lyophilized preparation should be kept at -20 °C with desiccation. However, it can also remain stable at 2-8 °C. Once reconstituted, the preparation should be used within one week if stored at 2-8 °C. To ensure maximum stability, it is recommended to divide the reconstituted preparation into smaller aliquots and store them at temperatures between -20 °C and -70 °C. It is important to avoid subjecting the preparation to repeated freeze/thaw cycles as it may affect its stability.

Target

Accession

P05000

Gene IDs

3467

References

References

1. Yang LM, Xue QH, Sun L, et al. 2007. J Interferon Cytokine Res, 27: 119-27.

2. Liu L, Leaman DW, Bixby JA, et al. 1996. Biochim Biophys Acta, 1294: 55-62.

3. Adolf GR. 1990. Virology, 175: 410-7.

4. Benoit P, Maguire D, Plavec I, et al. 1993. J Immunol, 150: 707-16.